Literature DB >> 2427572

Structure-function relationships for the IL 2-receptor system. I. Localization of a receptor binding site on IL 2.

L M Kuo, R J Robb.   

Abstract

Interleukin 2 (IL 2) modulates the growth and differentiation of a variety of lymphocyte subclasses through its interaction with a specific cell surface receptor. Although both IL 2 and its receptor have been characterized extensively, the location of interaction sites on the two molecules is unknown. Synthetic peptides based on the IL 2 sequence were used to determine the epitopes seen by a number of antibodies reactive with IL 2, some of which inhibited the receptor binding of the factor and the proliferative response of target cells. The results indicated that inhibitory antibodies bound at either of two spatially distinct sites defined by amino acids 8-27 and 33-54. By inference, these segments may also encode distinct contact sites for receptor association. Alternatively, a single contact site may be located between the antibody epitopes in the three-dimensional configuration of the molecule. Although the data did not directly address the role of the C-terminal portion of IL 2, this preliminary localization of receptor contact sites within the N-terminal half of the molecule should prove useful in correlating structure and function during crystallographic analysis of the factor.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2427572

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

Review 1.  Immunotherapy through the IL-2 receptor.

Authors:  H A Verheul; M Verveld; E S Bos
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

2.  Antibodies that neutralize human beta interferon biologic activity recognize a linear epitope: analysis by synthetic peptide mapping.

Authors:  P N Redlich; P D Hoeprich; C B Colby; S E Grossberg
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

3.  Insufficient (sub-native) helix content in soluble/solid aggregates of recombinant and engineered forms of IL-2 throws light on how aggregated IL-2 is biologically active.

Authors:  Uzma Fatima; Balvinder Singh; Karthikeyan Subramanian; Purnananda Guptasarma
Journal:  Protein J       Date:  2012-10       Impact factor: 2.371

4.  IL-2-like activity in lymph fluid following in vivo antigen challenge.

Authors:  R Bujdoso; P Young; J Hopkins; I McConnell
Journal:  Immunology       Date:  1990-01       Impact factor: 7.397

5.  Immunochemical localization of the epitope for a monoclonal antibody that neutralizes human platelet-derived growth factor mitogenic activity.

Authors:  W J LaRochelle; K C Robbins; S A Aaronson
Journal:  Mol Cell Biol       Date:  1989-08       Impact factor: 4.272

6.  Localization in human interleukin 2 of the binding site to the alpha chain (p55) of the interleukin 2 receptor.

Authors:  K Sauvé; M Nachman; C Spence; P Bailon; E Campbell; W H Tsien; J A Kondas; J Hakimi; G Ju
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

7.  Interleukin 2 binding molecule distinct from the Tac protein: analysis of its role in formation of high-affinity receptors.

Authors:  R J Robb; C M Rusk; J Yodoi; W C Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

8.  Identification of a direct interaction between interleukin 2 and the p64 interleukin 2 receptor gamma chain.

Authors:  S D Voss; T P Leary; P M Sondel; R J Robb
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

9.  Limited tryptic digestion of recombinant human interleukin-2: structure-binding relationships with the alpha chain of the interleukin-2 receptor.

Authors:  K Hollfelder; F Rabban; F Wang; Y C Pan
Journal:  J Protein Chem       Date:  1993-08

10.  Recombinant interleukin-2 acts like a class I antiarrhythmic drug on human cardiac sodium channels.

Authors:  T Proebstle; M Mitrovics; M Schneider; V Hombach; R Rüdel
Journal:  Pflugers Arch       Date:  1995-02       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.